- Conditions
- Hypothalamic Obesity
- Interventions
- Exenatide
- Drug
- Lead sponsor
- Children's Hospitals and Clinics of Minnesota
- Other
- Eligibility
- 10 Years to 21 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2019
- U.S. locations
- 2
- States / cities
- Orange, California • Saint Paul, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–32
of 8
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Craniopharyngioma, Hypothalamic Obesity
- Interventions
- Syntocinon, Placebo (for Syntocinon)
- Drug
- Lead sponsor
- Shana McCormack, MD
- Other
- Eligibility
- 10 Years to 35 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic Form, Septo-Optic Dysplasia, Optic Nerve Hypoplasia, Childhood-onset Combined Pituitary Hormone Deficiency, Pituitary Stalk Interruption Syndrome
- Interventions
- Setmelanotide, Placebo
- Drug
- Lead sponsor
- Rhythm Pharmaceuticals, Inc.
- Industry
- Eligibility
- 4 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Aurora, Colorado • Chicago, Illinois + 5 more
- Conditions
- Metabolic Syndrome, Hypogonadism
- Interventions
- Testosterone gel, Placebo for testosterone gel
- Radiation · Drug
- Lead sponsor
- McGuire Research Institute
- Other
- Eligibility
- 20 Years to 65 Years · Male only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Type 2 Diabetic Male With Hypogonadotrophic Hypogonadism
- Interventions
- androgel, placebo
- Drug
- Lead sponsor
- University at Buffalo
- Other
- Eligibility
- 31 Years to 60 Years · Male only
- Enrollment
- 47 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2018
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Hypogonadotropic Hypogonadism
- Interventions
- BGS649, Placebo
- Drug
- Lead sponsor
- Mereo BioPharma
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 271 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 45 more
- Conditions
- Obese Hypogonadotropic Hypogonadism
- Interventions
- Investigational new drug company code: BGS649, Placebo
- Drug
- Lead sponsor
- Mereo BioPharma
- Industry
- Eligibility
- 30 Years to 65 Years · Male only
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 4
- States / cities
- Tucson, Arizona • San Diego, California • Miramar, Florida + 1 more
- Conditions
- Hypogonadism, Hypogonadotropic, Obesity
- Interventions
- anastrozole (1 mg/day), Placebo
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 40 Years to 65 Years · Male only
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas